OR.PA : Summary for L''OREAL - Yahoo Finance

U.S. Markets closed
Loading...
Loading...
  • Reuters2 days ago

    GSK grabs Astra executive to replace pharma head

    LONDON/DAVOS, Switzerland, Jan 19 (Reuters) - G laxoSmithKline's global head of pharmaceuticals, Abbas Hussain, is to leave Britain's biggest drugmaker after being passed over for the top job and will be replaced by Luke Miels from AstraZeneca. Hussain, the brother of former England cricket captain Nasser Hussain, had been a contender to take over from Chief Executive Andrew Witty, who steps down at the end of March, but the job went to GSK's consumer health boss Emma Walmsley.

  • Reuters11 days ago

    Valeant to sell assets for $2.12 billion to ease debt load

    Valeant's U.S.-listed shares (VRX.N) rose as much as 14 percent on Tuesday, before paring gains to 5.7 percent at $16.22 in afternoon trading. Laval, Quebec-based Valeant has been the subject of recent investigations by congressional panels as well as the Federal Trade Commission and the U.S. Securities and Exchange Commission. French cosmetics group L'Oreal (OREP.PA) is buying CeraVe, AcneFree and Ambi from Valeant for about $1.3 billion in cash.

  • Benzinga11 days ago

    Valeant's Asset Sale To L'Oreal Explained

    Valeant Pharmaceuticals Intl Inc (NYSE: VRX ) announced an agreement to sell its CeraVe, AcneFree and AMBI Skincare brands to L'Oreal SA (ADR) (OTC: LRLCY ) for $1.3 billion. According to Gadfly's Andrea ...